GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (OTCPK:CYDY) » Definitions » Volatility

CytoDyn (CytoDyn) Volatility : 75.86% (As of May. 20, 2024)


View and export this data going back to 2005. Start your Free Trial

What is CytoDyn Volatility?

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2024-05-20), CytoDyn's Volatility is 75.86%.


Competitive Comparison of CytoDyn's Volatility

For the Biotechnology subindustry, CytoDyn's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytoDyn's Volatility Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoDyn's Volatility distribution charts can be found below:

* The bar in red indicates where CytoDyn's Volatility falls into.



CytoDyn  (OTCPK:CYDY) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * 12
= 1/(n-1) ∑(Ri - R')^2 * 12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CytoDyn  (OTCPK:CYDY) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.


CytoDyn Volatility Related Terms

Thank you for viewing the detailed overview of CytoDyn's Volatility provided by GuruFocus.com. Please click on the following links to see related term pages.


CytoDyn (CytoDyn) Business Description

Traded in Other Exchanges
Address
1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a US-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The lead product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
Executives
Tyler Blok officer: EVP of Legal Affairs 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Stephen M Simes director
Ryan Dunlap director 310 N. STATE STREET, SUITE 208, LAKE OSWEGO OR 97034
Arvin Cyrus Arman officer: President 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Karen J Brunke director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Tanya Durkee Urbach director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Lishomwa C Ndhlovu director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Harish Seethamraju director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Alan P Timmins director 1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Gordon A Gardiner director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Samir Rashmikant Patel director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Antonio Migliarese officer: Chief Financial Officer 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Chris P Recknor officer: Chief Operating Officer 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Michael D. Mulholland officer: CFO, Treasurer and Secretary 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Jordan G Naydenov director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660

CytoDyn (CytoDyn) Headlines